Research: Paxlovid of no benefit to the under-65’s

Coronavirus, Health, Hospitalization, Paxlovid, Paxlovid Rebound, Preprint, Research, Symptoms

“Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. No evidence of benefit was found in younger adults.”

A total of 109,254 patients met the eligibility criteria, of whom 3902 (4%) received nirmatrelvir during the study period. Among patients 65 years of age or older, the rate of hospitalization due to Covid-19 was 14.7 cases per 100,000 person-days among treated patients as compared with 58.9 cases per 100,000 person-days among untreated patients.

Among patients 40 to 64 years of age, the rate of hospitalization due to Covid-19 was 15.2 cases per 100,000 person-days among treated patients and 15.8 cases per 100,000 person-days among untreated patients.

NEJM article: Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

 

 

 

Science Mag: SARS-CoV-2 already finding ways to evade Paxlovid

 

 

 Photo by Start Digital on Unsplash